Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$0.94 -2.1%	$0.97	$0.46 ▼ $7.49	$5.04M	-0.17	617,802 shs	21,897 shs
CMRX Chimerix	$8.54	$8.54	$0.75 ▼ $8.55	$801.09M	-0.17	2.84 million shs	N/A
CTST CannTrust	C$0.64	C$0.64	C$0.38 ▼ C$8.17	C$90.27M	N/A	N/A	N/A
FPRX Five Prime Therapeutics	$38.00	$37.94	$2.61 ▼ $38.90	$1.77B	4.4	1.98 million shs	N/A
ZYNE Zynerba Pharmaceuticals	$1.30	$1.30	$0.25 ▼ $1.40	$70.12M	1.32	515,333 shs	N/A

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	+1.18%	+6.36%	-17.13%	-11.76%	-78.96%
CMRX Chimerix	0.00%	0.00%	0.00%	-0.12%	+850.47%
CTST CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
FPRX Five Prime Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ZYNE Zynerba Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APM Aptorum Group	2.084 of 5 stars	0.0	5.0	0.0	0.0	3.8	1.7	0.6
CMRX Chimerix	0.5635 of 5 stars	1.0	0.0	0.0	4.1	0.0	1.7	0.6
CTST CannTrust	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FPRX Five Prime Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	0.00	N/A	N/A	N/A
CMRX Chimerix	2.00	Hold	$8.53	-0.08% Downside
CTST CannTrust	0.00	N/A	N/A	N/A
FPRX Five Prime Therapeutics	0.00	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	11.72	N/A	N/A	$2.20 per share	0.43
CMRX Chimerix	$212K	3,778.71	N/A	N/A	$2.17 per share	3.94
CTST CannTrust	C$35.22M	2.56	N/A	N/A	N/A	∞
FPRX Five Prime Therapeutics	$14.87M	119.01	N/A	N/A	$4.13 per share	9.20
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	$1.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$4.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	7/30/2025 (Estimated)
CMRX Chimerix	-$82.10M	-$0.99	N/A	N/A	N/A	N/A	-50.78%	-44.94%	8/11/2025 (Estimated)
CTST CannTrust	-C$10.46M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
FPRX Five Prime Therapeutics	-$137.20M	-$3.92	N/A	N/A	N/A	-554.71%	-75.84%	-49.08%	N/A
ZYNE Zynerba Pharmaceuticals	-$35.04M	-$0.80	N/A	N/A	N/A	N/A	-90.03%	-72.62%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
CMRX Chimerix	N/A	N/A	N/A	N/A	N/A
CTST CannTrust	N/A	N/A	N/A	N/A	N/A
FPRX Five Prime Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.22	0.22
CMRX Chimerix	N/A	6.33	6.33
CTST CannTrust	N/A	N/A	N/A
FPRX Five Prime Therapeutics	N/A	5.35	5.35
ZYNE Zynerba Pharmaceuticals	N/A	3.43	3.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
CMRX Chimerix	45.42%
CTST CannTrust	0.03%
FPRX Five Prime Therapeutics	67.28%
ZYNE Zynerba Pharmaceuticals	11.23%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
CMRX Chimerix	13.10%
CTST CannTrust	N/A
FPRX Five Prime Therapeutics	6.40%
ZYNE Zynerba Pharmaceuticals	13.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	5.35 million	1.93 million	Not Optionable
CMRX Chimerix	90	93.80 million	78.15 million	Optionable
CTST CannTrust	576	141.49 million	N/A	Optionable
FPRX Five Prime Therapeutics	87	46.57 million	N/A	Optionable
ZYNE Zynerba Pharmaceuticals	25	53.94 million	46.91 million	Optionable

FPRX, CMRX, ZYNE, CTST, and APM Headlines

Recent News About These Companies

22q11.2 Deletion Syndrome Market Research Report 2025: Zynerba Pharmaceuticals is at the Forefront with Its Clinical-stage Therapy Zygel (ZYN002)

June 25, 2025 | globenewswire.com

Harmony Biosciences: If It Ain't Broke

June 5, 2025 | seekingalpha.com

US Penny Stocks To Watch In October 2024

October 28, 2024 | uk.finance.yahoo.com

Discover 3 US Penny Stocks With Market Caps Over $70M

October 24, 2024 | uk.finance.yahoo.com

Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight

October 22, 2024 | uk.finance.yahoo.com

GW Pharma's cannabis-derived epilepsy drug approved in EU

October 7, 2024 | pharmaphorum.comP

Fragile X Syndrome Therapeutic Pipeline Research Report 2024 Featuring Zynerba, Tetra Discovery Partners, Nova Mentis, Neuren Pharmaceuticals, and Tetra Discovery Partners

July 31, 2024 | globenewswire.com

Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results

October 31, 2023 | finance.yahoo.com

Why Shares of Harmony Bioscience Are Falling on Friday

October 13, 2023 | fool.com

New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies

October 11, 2023 | markets.businessinsider.com

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE

October 11, 2023 | finance.yahoo.com

H.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)

October 10, 2023 | knoxdaily.comK

Analysts: ZYNE stock price target of $1.25 in 12 months

October 5, 2023 | knoxdaily.comK

Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions

October 4, 2023 | finance.yahoo.com

Examining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)

October 2, 2023 | knoxdaily.comK

20 Countries With Highest Rate of Epilepsy

September 29, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023

September 29, 2023 | finance.yahoo.com

Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal

September 27, 2023 | bizjournals.com

Zynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Rise

September 25, 2023 | knoxdaily.comK

Zynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwright

September 20, 2023 | knoxdaily.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

FPRX, CMRX, ZYNE, CTST, and APM Company Descriptions

Aptorum Group NASDAQ:APM

$0.94 -0.02 (-2.13%)

Closing price 03:58 PM Eastern

Extended Trading

$0.94 +0.00 (+0.21%)

As of 04:14 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Chimerix NASDAQ:CMRX

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

CannTrust NYSE:CTST

CannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Five Prime Therapeutics NASDAQ:FPRX

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Zynerba Pharmaceuticals NASDAQ:ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time